G1 Therapeutics
Utility Patents

Last updated:

List of all G1 Therapeutics patents 24 in total

Status Patent
Grant
Utility: Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors External link
Filling date: 26 Sep 2025 Issue date: 20 Sep 2022
Grant
Utility: Treatment of EGFR-driven cancer with fewer side effects External link
Filling date: 26 Sep 2025 Issue date: 26 Jul 2022
Grant
Utility: Combination therapy for treatment of cancer External link
Filling date: 26 Sep 2025 Issue date: 21 Jun 2022
Grant
Utility: G1T38 superior dosage regimes External link
Filling date: 26 Sep 2025 Issue date: 14 Jun 2022
Grant
Utility: Morphic forms of G1T38 and methods of manufacture thereof External link
Filling date: 26 Sep 2025 Issue date: 1 Mar 2022
Grant
Utility: Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors External link
Filling date: 26 Sep 2025 Issue date: 17 Aug 2021
Grant
Utility: Transient protection of normal cells during chemotherapy External link
Filling date: 26 Sep 2025 Issue date: 22 Jun 2021
Grant
Utility: Morphic forms of trilaciclib and methods of manufacture thereof External link
Filling date: 26 Sep 2025 Issue date: 27 Apr 2021
Grant
Utility: Benzothiophene estrogen receptor modulators External link
Filling date: 26 Sep 2025 Issue date: 20 Apr 2021
Grant
Utility: Transient protection of normal cells during chemotherapy External link
Filling date: 26 Sep 2025 Issue date: 6 Apr 2021
Grant
Utility: CDK inhibitors External link
Filling date: 26 Sep 2025 Issue date: 23 Feb 2021
Grant
Utility: HSPC-sparing treatments for RB-positive abnormal cellular proliferation External link
Filling date: 26 Sep 2025 Issue date: 23 Feb 2021
Grant
Utility: Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines External link
Filling date: 26 Sep 2025 Issue date: 15 Dec 2020
Grant
Utility: Substituted dihydropyrazino[1 ',2':1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents External link
Filling date: 26 Sep 2025 Issue date: 10 Nov 2020
Grant
Utility: Highly active anti-neoplastic and anti-proliferative agents External link
Filling date: 26 Sep 2025 Issue date: 14 Jul 2020
Grant
Utility: CDK inhibitors External link
Filling date: 26 Sep 2025 Issue date: 30 Jun 2020
Grant
Utility: Transient protection of normal cells during chemotherapy External link
Filling date: 26 Sep 2025 Issue date: 26 May 2020
Grant
Utility: Antiproliferative pyrimidine-based compounds External link
Filling date: 26 Sep 2025 Issue date: 19 May 2020
Grant
Utility: Benzothiophene estrogen receptor modulators External link
Filling date: 26 Sep 2025 Issue date: 28 Apr 2020
Grant
Utility: Pyrimidine-based compounds for the treatment of cancer External link
Filling date: 26 Sep 2025 Issue date: 14 Apr 2020
Grant
Utility: Lactam kinase inhibitors External link
Filling date: 26 Sep 2025 Issue date: 5 Nov 2019
Grant
Utility: HSPC-sparing treatments for Rb-positive abnormal cellular proliferation External link
Filling date: 26 Sep 2025 Issue date: 8 Oct 2019
Grant
Utility: Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors External link
Filling date: 26 Sep 2025 Issue date: 17 Sep 2019
Grant
Utility: Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation External link
Filling date: 26 Sep 2025 Issue date: 13 Aug 2019

Showing 1 to 24 of 24 patents.